Business
Median Technologies submits U.S. application for 510(k) clearance of eyonis® LCS
SOPHIA ANTIPOLIS, France, May 14, 2025--Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, "Median" or the "Company"), manufacturer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, today announced it has filed an application to the U.S. Food and Drug Administration (FDA) fo
About this update from Median Technologies
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1240,"height":461,"url":"https://media.zenfs.com/en/business-wire.com/12aeb3ce0436adaf6fed07ddbb6a69ca"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/iSOazvL07As3YzC.EvN2Zw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM1NztjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/12aeb3ce0436adaf6fed07ddbb6a69ca","width":960,"height":357},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/t.FhcdPLfCOxqNh.8soLDA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04OTI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/12aeb3ce0436adaf6fed07ddbb6a69ca","width":1200,"height":446}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Submission based on positive data from two pivotal studies, which both met their primary endpoints","length":98,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"U.S. clearance expected in Q3 2025 based on average observed review timelines for radiological medical devices","length":110,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":208,"olType":false},{"type":"text","content":"SOPHIA ANTIPOLIS, France, May 14, 2025--(BUSINESS WIRE)--Regulatory News:","length":73,"tagName":"p"},{"type":"text","content":"Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, "Median" or the "Company"), manufacturer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, today announced it has filed an application to the U.S. Food and Drug Administration (FDA) for 510(k) clearance of eyonis® LCS, its AI/ML tech-based SaMD for computer aided detection and diagnosis (CADe/CADx) in lung cancer screening.","length":604,"tagName":"p"},{"type":"text","content":"The submission is based on positive data from the two pivotal studies of eyonis® LCS, REALITY and RELIVE, both of which met their primary endpoints. This data demonstrated that eyonis® LCS provides robust diagnostic performance for early detection and characterization of lung nodules in high-risk lung cancer populations, with significant potential to impact patients’ clinical outco...